AMRX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
The stock trades at a premium to its intrinsic value due to high growth expectations, but the trailing P/E suggests overvaluation relative to current earnings.
- Forward P/E of 10.12 appears attractive
- Intrinsic value estimate of $1.54 suggests undervaluation
- Trailing P/E of 53.77 is extremely high
- Negative Price/Book ratio indicates asset overvaluation
- No Graham Number available, limiting defensive valuation
The company shows strong forward-looking growth momentum, but the sustainability of such growth is questionable given the deteriorating financial health.
- 11.5% YoY revenue growth
- 75% YoY EPS growth
- Strong earnings surprise history (avg +26.6%)
- No PEG ratio available
- Forward P/E may not reflect sustainable growth
Historical performance shows strong momentum, but recent price weakness and inconsistent results suggest a potential reversal.
- Consistent earnings beat rate (3 of last 4 quarters)
- High average earnings surprise (+26.6%)
- Positive 3-year return (+727.3%)
- Two quarters with negative surprises (-21.1% and -20.6%)
- Declining 1-month and 1-week performance (-19.5%, -10.7%)
The company exhibits severe financial distress risk due to extreme leverage and weak operational metrics, despite some liquidity.
- Current ratio of 2.17 and quick ratio of 1.39 indicate short-term liquidity
- Piotroski F-Score of 4/9 is below threshold for stability
- Debt/Equity ratio of 450.96 is dangerously high
- No Altman Z-Score available, but debt levels imply distress risk
The company does not pay dividends, which limits income appeal and may reflect reinvestment of capital due to high leverage.
- No dividend yield or payout ratio
- Dividend Strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AMRX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
Primary
|
+69.5% | +727.3% | +34.6% | +18.3% | -19.5% | -10.7% |
|
TVTX
Travere Therapeutics, Inc.
Peer
|
+55.7% | +89.8% | +166.6% | +44.5% | +50.1% | +31.2% |
|
IRTC
iRhythm Holdings, Inc.
Peer
|
+43.4% | -13.2% | +16.6% | -34.6% | -3.7% | -1.3% |
|
TLX
Telix Pharmaceuticals Limited
Peer
|
-29.2% | -29.2% | -33.8% | -0.6% | +22.6% | -4.5% |
|
INDV
Indivior Pharmaceuticals, Inc.
Peer
|
+218.1% | +75.0% | +241.6% | +28.4% | -7.0% | +0.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
BEARISH | $3.72B | 53.77 | -% | 2.4% | $11.83 | |
|
TVTX
Travere Therapeutics, Inc.
|
BULLISH | $3.72B | - | -57.8% | -5.2% | $40.29 | Compare |
|
IRTC
iRhythm Holdings, Inc.
|
NEUTRAL | $3.72B | - | -36.6% | -6.0% | $115.24 | Compare |
|
TLX
Telix Pharmaceuticals Limited
|
NEUTRAL | $3.64B | - | -1.9% | -0.9% | $10.73 | Compare |
|
INDV
Indivior Pharmaceuticals, Inc.
|
NEUTRAL | $3.82B | 18.62 | -% | 16.9% | $30.54 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | PATEL CHIRAG K | Chief Executive Officer | Stock Award | 886,468 | - |
| 2026-03-04 | SHAH NIKITA | Officer | Stock Award | 508,499 | - |
| 2026-03-04 | PATEL CHINTU | Chief Executive Officer | Stock Award | 886,468 | - |
| 2026-03-04 | DALY JASON B. | Officer | Stock Award | 426,819 | - |
| 2026-03-04 | KONIDARIS TASOS | Chief Financial Officer | Stock Award | 633,865 | - |
| 2026-03-04 | BOYER ANDREW S | Officer | Stock Award | 548,953 | - |
| 2025-11-17 | NARK THEODORE C. | Director | Sale | 50,000 | $586,000 |
| 2025-11-12 | SHAH NIKITA | Officer | Option Exercise | 131,856 | $362,604 |
| 2025-11-12 | SHAH NIKITA | Officer | Sale | 131,856 | $1,571,724 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning AMRX from our newsroom.